NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CITANEST FORTE (epinephrine bitartrate; prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CITANEST FORTE is a combination local anesthetic injectable containing prilocaine hydrochloride and epinephrine bitartrate, approved in 1965. Prilocaine stabilizes neuronal membranes to block pain signal conduction, while epinephrine provides vasoconstriction to prolong anesthetic effect and reduce systemic absorption. It is used for infiltration, nerve block, and topical anesthesia in minor surgical and dental procedures.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30) suggests limited team expansion and focus on cost management or market defense strategies.
Mechanism of Action
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CITANEST FORTE offers limited high-growth career momentum due to its LOE-approaching status and zero linked job openings; however, it provides valuable experience in managing mature, stable products and defending against generic competition in a cost-conscious healthcare environment. This role is best suited for professionals seeking to build expertise in lifecycle management and market sustainability rather than new product launches.
Brand Manager
Worked on CITANEST FORTE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.